Publication:
First steps in the formulation of praziquantel nanosuspensions for pharmaceutical applications.

dc.contributor.authorMartínez, Noelia A
dc.contributor.authorFernández-Álvarez, Fátima
dc.contributor.authorDelgado, Ángel V
dc.contributor.authorBadillo-García, María Luisa
dc.contributor.authorRaba, Julio
dc.contributor.authorCerutti, Soledad E
dc.contributor.authorArias, José L
dc.date.accessioned2023-02-08T14:46:45Z
dc.date.available2023-02-08T14:46:45Z
dc.date.issued2020-04-25
dc.description.abstractPraziquantel (PZQ), a broad spectrum anthelmintic drug, cannot be found in acceptable dosage forms for elderly patients, paediatric patients, and for veterinary use. In fact, very little has been done up to now in the formulation of liquid dosage forms, being they always formulated for parenteral administration. To beat this important challenge, it was accomplished a comprehensive analysis of the influence of two elementary physicochemical aspects, i.e. surface thermodynamic and electrokinetic properties, on the colloidal stability of PZQ nanosuspensions. The hydrophobic character of the drug, intensely determining the flocculation curves, was confirmed by the thermodynamic characterization. The electrophoretic characterization, in combination with the sedimentation and relative absorbance versus time curves, highlighted that the electrical double layer thickness and the surface charge can play an essential role in the stability of the pharmaceutical colloid. Finally, it was demonstrated that controlling the pH values and the incorporation of electrolytes can help in formulating PZQ aqueous nanosuspensions with appropriate stability and redispersibility behaviours for pharmaceutical use.
dc.identifier.doi10.1080/10837450.2020.1756320
dc.identifier.essn1097-9867
dc.identifier.pmid32321344
dc.identifier.unpaywallURLhttps://ri.conicet.gov.ar/bitstream/11336/138054/2/CONICET_Digital_Nro.17fd924e-6bb9-4684-b6d2-bb3b9d650b0f_A.pdf
dc.identifier.urihttp://hdl.handle.net/10668/15413
dc.issue.number7
dc.journal.titlePharmaceutical development and technology
dc.journal.titleabbreviationPharm Dev Technol
dc.language.isoen
dc.organizationServicio Andaluz de Salud-SAS
dc.organizationServicio Andaluz de Salud-SAS
dc.page.number892-898
dc.pubmedtypeJournal Article
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCorrelation zeta potential – sedimentation
dc.subjectelectrophoresis
dc.subjecthuman and veterinary liquid dosage forms
dc.subjectpaediatric drug formulations
dc.subjectpraziquantel
dc.subjectsurface thermodynamics
dc.subject.meshAnthelmintics
dc.subject.meshChemistry, Pharmaceutical
dc.subject.meshDrug Compounding
dc.subject.meshElectrolytes
dc.subject.meshHydrogen-Ion Concentration
dc.subject.meshHydrophobic and Hydrophilic Interactions
dc.subject.meshNanospheres
dc.subject.meshPraziquantel
dc.subject.meshWater
dc.titleFirst steps in the formulation of praziquantel nanosuspensions for pharmaceutical applications.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number25
dspace.entity.typePublication

Files